

## LISTING OF THE CLAIMS

1. (Currently Amended). A formulation comprising i) fenofibric acid; or a physiologically acceptable salt ~~or derivative~~ thereof, and optionally, other active substances; ii) a binder component comprising at least one enteric binder; and optionally, iii) other physiologically acceptable excipients.

2. (Canceled).

3. (Currently Amended). The formulation as claimed in claim 1, wherein the fenofibric acid; or the physiologically acceptable salt ~~or derivative~~ thereof is in the form of a molecular dispersion.

4. (Original). The formulation as claimed in claim 1, wherein the enteric binder is an enteric polymer.

5. (Original). The formulation as claimed in claim 4, wherein the enteric polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium.

6. (Original). The formulation as claimed in claim 4, wherein the enteric polymer is selected from copolymers based on (meth)acrylic acid and at least one alkyl (meth)acrylic acid ester.

7. (Original). The formulation as claimed in claim 6, wherein the alkyl (meth)acrylic acid ester is methyl methacrylate.

8. (Original). The formulation as claimed in claim 6, wherein the copolymer has a ratio of free carboxyl groups to esterified carboxyl groups of around 2:1 to 1:3.

9. (Original). The formulation of claim 8, wherein the ratio is around 1:1.

10. (Currently Amended). The formulation as claimed in claim 1, wherein the formulation comprises i) 5 to 60% by weight, ~~preferably 7 to 40% by weight and in particular 10 to 30% by weight~~ of active substances component; ii) 20 to 95% by weight, ~~preferably 30 to 90% by weight and in particular 40 to 85% by weight~~, of a binder component; iii) 0 to 75% by weight, ~~preferably 1 to 60% by weight and in particular 5 to 40% by weight~~, of other physiologically acceptable excipients.

11. (Currently Amended). The formulation as claimed in claim 1, wherein the enteric binder preferably constitutes 5 to 95% by weight, ~~more preferably 10 to 70% by weight and, in particular, 30 to 60% by weight~~ of the binder component (ii).

12. (Currently Amended). The formulation as claimed in claim 1, wherein the content of active substances ~~component (i)~~ relative to the binder component (ii) is from 1 to 50% by weight, ~~preferably 10 to 40% by weight and in particular 20 to 30% by weight.~~

13. (Currently Amended). The formulation as claimed in claim 1, wherein the binder is an enteric polymer and the physiologically acceptable excipient is a flow regulator comprising i) fenofibric acid or fenofibrate; ii) at least one binder selected from enteric polymers; and optionally iii) other physiologically acceptable excipients, especially a flow regulator, e.g. highly disperse silica gel.

14. (Currently Amended). The formulation as claimed in claim 1, wherein said formulation is obtainable by melt extrusion of a mixture comprising a fenofibric acid, a physiologically or a physiologically acceptable salt or derivative thereof, a binder and optionally, other active substances and/or other physiologically acceptable excipients.

15. (Currently Amended). A method for oral administration of fenofibric acid, or a physiologically acceptable salt ~~or derivative~~ thereof, comprising administering a formulation as claimed in claim 1, optionally, with the addition of other excipients, as a dosage form.

16. (Currently Amended). ~~A~~ D dosage form comprising a formulation as claimed in claim 1.

17. (New). The formulation as claimed in claim 10, wherein the formulation comprise i) 7 to 40% by weight of active substances; ii) 30 to 90% by weight of a binder component; and iii) 1 to 60% by weight of other physiological excipients.

18. (New). The formulation as claimed in claim 17, wherein the formulation comprise i) 10 to 30% by weight of active substances; ii) 40 to 85% by weight of a binder component; and iii) 5 to 40% by weight of other physiological excipients.

19. (New). The formulation as claimed in claim 11, wherein the enteric binder constitutes 10 to 70% by weight of the binder component (ii).

20. (New). The formulation as claimed in claim 19, wherein the enteric binder constitutes 30 to 60% by weight of the binder component (ii).

21. (New). The formulation as claimed in claim 12, wherein the content of the active substances (i) relative to binder component (ii) is from 10 to 40% by weight.

22. (New). The formulation as claimed in claim 21, wherein the content of the active substances (i) relative to binder component (ii) is from 20 to 30% by weight.